Penumbra announced the latest STRIKE-PE data evaluating Penumbra’s Indigo Aspiration System with Lightning. The results show Penumbra’s computer assisted vacuum thrombectomy – CAVT – is safe and effective at reducing right heart strain. It also improved clinical outcomes, including heart rate and respiratory rate, and functional outcomes when used to treat acute high and intermediate risk pulmonary embolism, or PE. Penumbra’s CAVT is designed to allow physicians to remove large blood clots in the body safely. The interim results of the study which evaluated Penumbra’s Lightning technology in 150 of 600 anticipated patients to be enrolled, include: low 48hr major adverse event rate of 2.7%, low 48hr major bleeding rate of 2.7%, reduction of right ventricle/left ventricle ratio by 25.7%. Penumbra is also conducting STORM-PE, a first-of-its kind randomized controlled trial comparing CAVT using Penumbra’s Lightning Flash with anticoagulation versus anticoagulation alone, with the goal of showing the clinical benefits to patients who receive CAVT.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on PEN:
- Penumbra, Inc. Reports Third Quarter 2023 Financial Results
- 5 Top Mid-Cap Stocks to Buy Now, According to Analysts – October 2023
- 3 Best Stocks to Buy Now, 10/16/2023, According to Top Analysts
- Penumbra price target lowered to $240 from $345 at Truist
- 3 Best Stocks to Buy Now, 10/11/2023, According to Top Analysts
